Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

Status:
Completed
Trial end date:
2019-10-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925 when administered to healthy participants and narcolepsy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda